⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
Latest News
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
businesswire.com
XNCR
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
prnewswire.com
LLY
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
prnewswire.com
JNJ
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
globenewswire.com
BNTX
BMY
BeOne präsentiert auf der ESMO 2026 überzeugende Daten zu schwer zu behandelndem Leber- und Lungenkrebs
businesswire.com
ONC
BeOne apresenta dados convincentes sobre tipos de câncer de fígado e pulmão de difícil tratamento na ESMO 2026
businesswire.com
ONC
Shareholders of Flotek Industries, Inc. (FTK): Protect Your Rights Before October 26, 2026 – Contact Levi & Korsinsky
accessnewswire.com
FTK
Class Action Alert: Levi & Korsinsky Reminds Flotek Industries, Inc. (FTK) Investors of October 26, 2026 Deadline
accessnewswire.com
FTK
Lost Money on Duolingo, Inc. (DUOL)? Contact Levi & Korsinsky Before December 7, 2026 to Join Class Action
accessnewswire.com
DUOL
York Space Systems Inc (YSS) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of October 30, 2026 Deadline
accessnewswire.com
YSS